OverviewChartProfileKey statisticsFinancialsTechnicalNewsTraderScreen

BASILEA N/  CH0011432447  /

SIX Swiss Exchange
10/7/2024  5:31:27 PM Chg. +0.300 Volume Bid5:40:00 PM Ask5:40:00 PM Market Capitalization Dividend Y. P/E Ratio
45.050CHF +0.67% 15,606
Turnover: 701,391.050		 44.600Bid Size: 200 45.400Ask Size: 200 590.15 mill.CHF - 51.78
GlobeNewswire 8/27 European Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) an...
GlobeNewswire 8/21 Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone paym...
GlobeNewswire 8/13 Basilea reports strong 2024 half-year results and significantly increases full-year revenue and prof...
GlobeNewswire 7/9 ImCheck Appoints Stephan Braun as Chief Medical Officer
GlobeNewswire 6/20 Basilea partners oncology drug candidate lisavanbulin with Glioblastoma Foundation
GlobeNewswire 5/16 Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone paym...
GlobeNewswire 5/3 Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024
GlobeNewswire 4/24 Basilea shareholders approve all proposals of the board of directors at the annual general meeting
GlobeNewswire 4/9 Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics
GlobeNewswire 4/4 Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indicati...
GlobeNewswire 3/11 Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers mile...
GlobeNewswire 2/13 Basilea reports strong 2023 full-year results with profitability significantly above guidance, whils...
GlobeNewswire 1/19 Cresemba® sales in Latin America trigger first sales milestone payment to Basilea
GlobeNewswire 1/15 Basilea announces acquisition of preclinical antibiotics program from Spexis
GlobeNewswire 1/5 Basilea provides portfolio status update
GlobeNewswire 12/11/2023 Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the Unit...
GlobeNewswire 11/20/2023 Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers thir...
GlobeNewswire 11/13/2023 Basilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungal
GlobeNewswire 10/31/2023 Basilea announces exclusive license and option agreement for potential first-in-class clinical-stage...
GlobeNewswire 10/19/2023 Basilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold i...
GlobeNewswire 10/17/2023 Basilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023
GlobeNewswire 10/2/2023 Basilea announces FDA acceptance of New Drug Application for antibiotic ceftobiprole
GlobeNewswire 9/28/2023 Basilea announces New England Journal of Medicine publication of phase 3 data on ceftobiprole for th...
GlobeNewswire 8/15/2023 Basilea reports strong revenue and profit growth in first half-year 2023
GlobeNewswire 3/8/2022 Basilea reports preclinical data on anti-cancer activity of novel oncology drug candidate BAL0891 at...